Skip to content
TrialScanner

NCT05159518

A Study of PRT2527 in Participants With Advanced Solid Tumors

Phase 1CompletedPRLDLead

Registry record

Lead sponsor
Prelude Therapeutics Incorporated
Conditions
Sarcoma; Castrate Resistant Prostate Cancer; Hormone Receptor Positive HER2 Negative Breast Cancer; Non-small Cell Lung Cancer; Solid Tumors With Known MYC Amplification
Primary completion
Dec 6, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05159518 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05159518: A Study of PRT2527 in... | TrialScanner